US Bancorp’s Tourmaline Bio TRML Stock Holding History

US Bancorp’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-144	Closed	-$6.89K	–	4201
2025 Q3	$6.89K	Sell	144 -88	-38%	-$2.44K	﹤0.01%	3436
2025 Q2	$3.71K	Buy	232 +153	+194%	+$2.48K	﹤0.01%	3724
2025 Q1	$1.2K	Sell	79 -20	-20%	-$321	﹤0.01%	3965
2024 Q4	$2.01K	Buy	99 +79	+395%	+$1.99K	﹤0.01%	3856
2024 Q3	$514	Buy	+20	New	+$334	﹤0.01%	3947

US Bancorp's TRML Position: Q4 2025 in Review

US Bancorp sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 144 shares — an estimated $6.89K sold.

US Bancorp first reported a position in TRML in Q3 2024 and held it in 5 quarters. The position peaked at $6.89K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

US Bancorp reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
US Bancorp sold 144 Tourmaline Bio shares in Q4 2025, an estimated $6.89K.
US Bancorp first reported a position in Tourmaline Bio in Q3 2024 and held it in 5 quarters.
US Bancorp's Tourmaline Bio position peaked at $6.89K in Q3 2025.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on US Bancorp's 13F filing for Q4 2025, filed 30 Jan 2026.